Loading organizations...
§ Private Profile · New York City, NY, USA
Prevail Therapeutics is a technology company.
Prevail Therapeutics develops novel AAV-based gene therapies designed to target the underlying genetic causes of neurodegenerative diseases. The company’s approach focuses on correcting genetic defects implicated in severe conditions such as Parkinson's disease and Gaucher disease, aiming to provide disease-modifying treatments. Their platform leverages advanced gene therapy technology to deliver therapeutic genes directly to the affected neurological systems.
The company was founded in 2017 by Dr. Asa Abeliovich. His vision for Prevail Therapeutics emerged from a collaborative effort with The Silverstein Foundation for Parkinson's with GBA, driven by the profound insight that recent breakthroughs in human genetics could be translated into effective treatments for devastating neurodegenerative conditions. This foundational understanding sought to address the root causes of these disorders rather than merely managing symptoms.
Prevail Therapeutics aims to serve patient populations grappling with urgent unmet medical needs in neurological disorders where no disease-modifying therapies currently exist. The company's long-term vision centers on transforming the treatment landscape by developing precision medicines that can slow or even halt the progressive course of these debilitating diseases, ultimately improving patient outcomes.
Prevail Therapeutics has raised $125.0M across 2 funding rounds.
Prevail Therapeutics has raised $125.0M in total across 2 funding rounds.
Prevail Therapeutics has raised $125.0M across 2 funding rounds. Most recently, it raised $50.0M Series B in March 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2019 | $50M Series B | — | InterWest, Meritech Capital Partners, OrbiMed, Wildcat Ventures, AbbVie Ventures, Adage Capital Management, Alexandria Venture Investments, Boxer Capital, BVF Partners, EcoR1 Capital, Omega Funds, Pontifax, RA Capital Management, Surveyor Capital | Announced |
| Mar 1, 2018 | $75M Series A | — | InterWest, Meritech Capital Partners, OrbiMed, Wildcat Ventures, Adage Capital Management, Alexandria Venture Investments, Boxer Capital, BVF Partners, EcoR1 Capital, Omega Funds, Pontifax, RA Capital Management, Silverstein Foundation For Parkinson's With GBA | Announced |
Prevail Therapeutics has raised $125.0M in total across 2 funding rounds.
Prevail Therapeutics's investors include InterWest, Meritech Capital Partners, OrbiMed, Wildcat Ventures, AbbVie Ventures, Adage Capital Management, Alexandria Venture Investments, Boxer Capital, BVF Partners, EcoR1 Capital, Omega Funds, Pontifax.
Prevail Therapeutics is a biotechnology company developing gene therapies to target the genetic root causes of neurodegenerative diseases like Parkinson's and frontotemporal dementia, as well as rare conditions such as Gaucher disease, aiming to slow or stop disease progression rather than just manage symptoms[1][2]. It serves patients with urgent unmet needs in disease communities lacking effective treatments, leveraging AAV-based (adeno-associated virus) therapeutics focused on lysosomal dysfunction[2][3]. Since becoming a wholly owned subsidiary of Eli Lilly in 2021, Prevail benefits from Lilly's neuroscience expertise and global resources to advance its pipeline, including the lead program PR001 for genetic Parkinson's subsets[2][3].
Prevail Therapeutics was launched in 2017 in New York City through a partnership between The Silverstein Foundation for Parkinson’s with GBA (a patient-led research foundation), REGENXBIO (providing its NAV Technology Platform via an exclusive license), and OrbiMed, with an initial $75 million Series A financing to build a pipeline of gene therapies[2][3][4]. Co-founded by Asa Abeliovich, M.D., Ph.D., a Columbia University faculty member and expert in neurodegeneration (previously co-founder of Alector), who served as the inaugural CEO, the company emerged from the need to address underlying disease processes in Parkinson's and related disorders beyond symptom relief[3][4]. Early traction included advancing PR001 for GBA1 mutation-related Parkinson's, supported by the Silverstein Foundation's commitment to halting disease progression[3][4]. In 2021, Eli Lilly acquired Prevail as a wholly owned subsidiary, enhancing its development capabilities while retaining patient-centric focus[2].
Prevail rides the wave of advancing gene therapy technologies, particularly AAV vectors, amid rising understanding of genetic drivers in neurodegenerative diseases—a trend fueled by recent scientific breakthroughs in lysosomal biology and delivery platforms[2][3]. Timing is critical as neurodegenerative conditions like Parkinson's affect millions with no disease-modifying options, and regulatory momentum (e.g., FDA approvals for similar therapies) favors rapid pipeline advancement[1][2]. Market forces include aging populations, investor interest in biotech (evident in its Series A and Lilly acquisition), and Lilly's neuroscience dominance amplifying Prevail's influence[2][3][4]. It contributes to the ecosystem by validating gene therapies for CNS disorders, partnering with foundations to prioritize patient needs, and expanding treatment paradigms beyond symptom management[1][2].
Prevail is positioned to advance its gene therapy pipeline into later-stage trials, potentially delivering first-in-class options for genetic Parkinson's and related diseases, bolstered by Lilly's resources for manufacturing and commercialization[2]. Key trends like refined AAV capsids, combination therapies, and expanded genetic screening will shape its path, with clinical data readouts driving milestones[1][3]. Its influence may grow by influencing standards for patient-inclusive biotech development, evolving from startup innovator to integral Lilly neuroscience arm—ultimately helping transform limited-symptom management into genetic-root interventions for neurodegenerative patients[1][2].